Active ingredientMaribavirCat. No. P-M010-001CAS 176161-24-3Family · Pharmaceutical analytical standards
Maribavir
An oral antiviral against cytomegalovirus that blocks the viral kinase pUL97, regarded by the FDA as first in its class. Approved in the United States in 2021 and in Europe in 2022 for post-transplant infections that do not respond to other treatments. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It is a benzimidazole linked to a 'mirror-image' sugar: it contains ribose in the L form, whereas the natural nucleosides of DNA and RNA use the D form.
Go to the active ingredient →Active ingredientMaribavirCat. No. P-M010-001CAS 176161-24-3
Isotopically labelledMaribavir-d7Cat. No. P-M010-002
ImpurityMaribavir Impurity 1Cat. No. P-M010-003CAS 176161-52-7
Impurity4,5-Dichloro-o-phenylenediamineCat. No. P-M010-005CAS 5348-42-5No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.